Olaparib, AZD1390, ceralasertib, saruparib and consolidation durvalumab (CONCORDE) phase Ib platform study of novel DNA damage response inhibitor (DDRi) agents in combination with radiotherapy in non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Greystoke, Alastair
Oughton, Jamie B.
Brown, Sarah R.
Butterworth, Karl
Coyle, Victoria
Franks, Kevin
Hassani, Adam
Harrow, Stephen
Hatton, Matthew
Hiley, Crispin T.
Kendall, Jessica
Phillip, Rachel
Norris, Matthew
Ojo, Oluwaseun
Shaw, Paul
Walker, Fiona
Yang, Huiqi
Chalmers, Anthony J.
Faivre-Finn, Corinne
机构：
[1] Univ Newcastle, Northern Ctr Canc Care, Newcastle Upon Tyne, England
[2] Univ Leeds, Leeds Inst Clin Trials Res, Leeds, England
[3] Queens Univ Belfast, Belfast, North Ireland
[4] Leeds Teaching Hosp NHS Trust, Leeds, England
[5] Northern Ctr Canc Care, Newcastle Upon Tyne, England
[6] Edinburgh Canc Ctr, Western Gen Hosp, Edinburgh, Scotland
[7] Weston Pk Hosp, Sheffield, England
[8] Univ Coll Hosp London, London, England
[9] AstraZeneca, Cambridge, England
[10] Velindre Canc Ctr, Cardiff, Wales
[11] Cambridge Univ Hosp, Cambridge, England
[12] Univ Glasgow, Glasgow, Scotland
[13] Christie NHS Fdn Trust, Manchester, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS8119
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase IB study to evaluate efficacy and tolerability of olaparib (AZD2281) plus gefitinib in patients (P) with epidermal growth factor receptor (EGFR) mutation positive advanced non-small cell lung cancer (NSCLC) (NCT=1513174/GECP-GOAL)
    Garcia Campelo, Rosario
    Felip, Enriqueta
    Massuti, Bartomeu
    Majem, Margarita
    Carcereny Costa, Enric
    Palmero, Ramon
    Angel Molina-Vila, Miguel
    Martinez, Pablo
    Luis Marti-Ciriquian, Juan
    Alonso-Jaudenes Curbera, Guillermo
    Pallares, Cinta
    Cardenal, Felipe
    Carmen Gonzalez-Arenas, Maria
    Mayo-de las Casas, Clara
    Sanchez-Ronco, Maria
    Rosell, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [32] Phase II study of weekly carboplatin/gemcitabine plus concurrent thoracic radiotherapy (RT) followed by consolidation carboplatin/gemcitabine for inoperable stage III non-small cell lung cancer (NSCLC).
    Domine, Manuel
    Carames Sanchez, Cristina
    Lobo, Francisco
    Hernandez Guerrero, Tatiana Carolina
    Leon, Ana
    Casado, Victoria
    Rubio, Gustavo
    Ignacio Martin-Valades, Jose
    Izarzugaza, Yann
    Luis Arranz, Juan
    Moreno, Irene
    Correa Noguera, Andrea
    Zenzola, Victor
    Dorta, Miriam
    Casado, Susana
    Ruperez, Ana
    Hernandez Lopez, Roberto
    Moreno, Victor
    Garcia-Foncillas, Jesus
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [33] The proteasome inhibitor, bortezomib, in combination with gemcitabine (Gem) and carboplatin (Carbo) in advanced non-small cell lung cancer (NSCLC): Final results of a phase I California Cancer Consortium study.
    Davies, AM
    Lara, PN
    Lau, DH
    Mack, PC
    Gumerlock, PH
    Gandara, DR
    Schenkein, D
    Doroshow, JH
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 642S - 642S
  • [34] Preliminary results from a Phase I study with AZD9291: An irreversible inhibitor of epidermal growth factor receptor (EGFR) activating and resistance mutations in non-small cell lung cancer (NSCLC)
    Ranson, M.
    Pao, W.
    Kim, D. W.
    Kim, S. W.
    Ohe, Y.
    Felip, E.
    Planchard, D.
    Ghiorghiu, S.
    Cantarini, M.
    Jaenne, P. A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S15 - S15
  • [35] A single-arm phase Ib study of autologous cytokine-induced killer (CIK) cell immunotherapy in combination with sintilimab plus chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)
    Zhou, L.
    Zhang, X.
    Zhang, W.
    Liu, L.
    Xiubao, R.
    ANNALS OF ONCOLOGY, 2020, 31 : S1392 - S1392
  • [36] A phase II study of sequence-dependent docetaxel (D)/vinorelbine(V) DNA damage-induced apoptosis in patients with non-small cell lung cancer (NSCLC)
    Balana, C
    Monzo, M
    Martin, C
    Lopez, MP
    Nunez, L
    Rosell, R
    ANNALS OF ONCOLOGY, 1998, 9 : 100 - 100
  • [37] TG01, a new potent COX-2 inhibitor in combination with erlotinib in metastatic or recurrent non-small cell lung cancer (NSCLC) patients: A phase 1 study
    Reckamp, K. L.
    Patel, R.
    Chen, L.
    Gitlitz, B. J.
    Davies, A. M.
    Jezior, D.
    Zaknoen, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [38] Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with pembrolizumab in patients with advanced/metastatic breast or non-small cell lung cancer (NSCLC): A phase Ib, multicenter, study.
    Borghaei, Hossein
    Besse, Benjamin
    Bardia, Aditya
    Mazieres, Julien
    Popat, Sanjay
    Augustine, Bincy
    D'amelio, Anthony Michael
    Barrios, Daniel
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [39] Phase Ib study of recombinant human (rh)Apo2L/TRAIL in combination with paclitaxel, carboplatin, and bevacizumab (PCB) in patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Soria, J.
    Smit, E. F.
    Khayat, D.
    Besse, B.
    Burton, J.
    Yang, X.
    Hsu, M.
    Braun, A.
    Reese, D.
    Blackhall, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [40] Phase Ia/Ib study of RS-0139, a novel tumor-targeted delivery of docetaxel, in patients with recurrent, locally advanced, or metastatic non-small cell lung cancer (NSCLC)
    Orer, H. S.
    Nomak, G.
    Oksuzoglu, B.
    Senturk, R.
    Eralp, Y.
    Yumuk, F.
    Nomak, H.
    Sanyal, R.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1097 - S1097
12345